May 2018

May 15, 2018, 07:30 ET CRANBURY, N.J., May 15, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2018. Recent Highlights Bremelanotide – Under …

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018 Read More »

May 10, 2018, 04:30 ET CRANBURY, N.J., May 10, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2018 operating results on Tuesday, May 15, 2018 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management …

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018 Read More »

PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis; PL-8331 Evaluated in an Animal Model of Dry Eye CRANBURY, N.J., May 9, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, …

Palatin Technologies Presents Positive Preclinical MC1 Receptor Agonist Data at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts Read More »